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An endogenous ligand for the rat central sulfonylurea receptor has been evidenced in the rat central nervous ystem. 
The characteristics of this ligand (extraetibility, non-dialysability, chromatographic behaviour on different media, sen- 
sitivity to proteases) indicate that it is a neutral to slightly basic peptide. 
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1. INTRODUCTION 
The mode of  action of  hypoglycemic 
sulfonylureas, a class o f  drugs widely used for the 
management of  non-insulino-dependent diabetes 
mellitus [1], is now widely accepted as being the in- 
teraction with specific receptors present at the cell 
surface, both at the peripheral [2,3] and the central 
[4,5] levels. A receptor for a natural regulatory 
molecule (such as a hormone or a neuro-regulator) 
is composed of  a binding site, recognizing 
specifically the ligand and the related compounds,  
linked to an effector system (such as adenylate 
cyclase, phospholipase C, ionic pump, or ionic 
channel). As far as the sulfonylurea receptor is 
concerned, it has been clearly established that the 
binding site is specific for the different 
hypoglycemic sulfonylureas with respective af- 
finities in close relation with their in vivo biological 
activities [2-5]. Furthermore, an ionic channel is 
suspected to be the effector system linked to the 
sulfonylurea binding site, although some 
discrepancies appeared in the literature concerning 
its exact type, either an ATP-dependent K + [6 ,7 ] ,  
a Ca2+-dependent K + [8] o r  a voltage-dependent 
Ca 2+ [9] channel. Thus, the sulfonylurea receptor 
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displays all the characteristics of  a biologically 
relevant receptor for a still unknown endogenous 
ligand [5]. The presence of  sulfonylurea receptors 
in the rat central nervous system [4,5] prompted us 
to search for the possible presence in this tissue of  
an endogenous ligand for this receptor. 
2. MATERIALS  AND METHODS 
2.1. Sulfonylureas 
Glipizide, 1-cyclohexyl-3- [(p-[2-(5-methylpyrazinecarbox- 
amido)ethyl]phenyl)sulfonyl]urea, was a generous gift from 
Farmitalia Carlo Erba, Milan, Italy. Glibenclamide, 1-[(p- 
[2-(5 -chloro -o-anisamido)ethyl]phenyl)sulfonyl] -3 -c clohexyl- 
urea, from Laboratori Guidotti SPA was kindly donated by 
Centre de Recherche Pierre Fabre, Castres, France. Both are 
highly potent second generation sulfonylureas, widely used in 
the management of non-insulino-dependent diabetes mellitus. 
2.2. Binding assay 
This was performed as described previously [5]. Membranes 
were prepared from rat cerebral cortex by homogenization in a 
motor-driven glass-teflon Potter-Braun i  10 mM Tris-HCl, pH 
7.5 (10 up and down strokes at 1000 rpm), followed by differen- 
tial centrifugation: after a 600 x g centrifugation at 4°C for 
10 min, the supcrnatant was spun down at 46000 x g at the 
same temperature for 30 min. The resulting pellet was washed 
twice in 50 mM Tris-HCl, pH 7.5, and recentrifuged. Mem- 
branes were incubated at 0.4 mg membrane protein/ml for 
60 min at room temperature with 0.1 nM [3H]Glibenclamide 
(40 Ci/mmol, from Hoechst, FRG) or with 2.5 nM 
[3H]Glipizide (21 Ci/mmol, a generous gift from Carlo Erba, 
Italy) in 1 ml of 50 mM Tris-HC1, pH 7.5, and, whenever 
necessary, unlabelled sulfonylurea t adequate concentrations 
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or the biological samples. Separation of bound from free 
sulfonylurea was performed by filtration on GF/B glass fiber 
filters (Whatman, England) under vacuum. The filters were 
quickly washed 3 times with 5 ml incubation buffer at 0°C 
before 3H counting in a scintillation medium (ACS II from 
Amersham, England). For each experiment, a standard curve 
was drawn from data obtained with unlabelled sulfonylurea and 
the sulfonylurea equivalent in each biological sample (crude ex- 
tract or chromatographic fraction) was calculated by reference 
to the standard curve. Only fresh membranes were used 
throughout. 
2.3. Tissue extractions 
Two types of extraction were performed. One consisted in 
taking as the extract the supernatant of the membrane prepara- 
tion. This corresponds to a mild extraction method using a 
homogenization i  a hypotonic medium, which is known to 
disrupt he nerve terminals and to liberate their content (in par- 
ticular the neurotransmitters) in the medium. The second con- 
sisted of a classical heat-coagulation/acid extraction method 
[10] widely used for peptide isolation. Briefly, the tissues were 
immersed for 3 min in boiling water and allowed to cool down. 
The tissues were then homogenized with a rotary blade ap- 
paratus in 1 M CH3COOH (5 ml/g of tissue) and lyophilized or 
run directly on a chromatography column. 
2.4. Purification methods 
High-performance liquid chromatography (HPLC) was per- 
formed with an apparatus consisting of two solvent delivery 
systems (6000A, Waters Associates, France) controlled by a 
gradient controller (720 from Waters) and a U6K injector 
(Waters) fitted with reverse-phase columns (Lichrosorb RP-8 
from Merck, FRG, Nucleosil CN from Soci6t6 Fran~aise 
Chromato Colonne, France, or/zC-18 from Waters). Gradient 
elution was conducted as indicated in the legend to the respec- 
tive figure. Fractions were collected in glass tubes with a frac- 
tion collector (1220 Isco, USA) and lyophilized after 
evaporation of the organic solvent under vacuum (Speed- 
Vac ® , Savant Instruments, USA). Sep-Pak separations were 
performed by running the extracts on C-18 reverse-phase car- 
tridges (Sep-Pak ® from Waters) previously equilibrated in 1% 
CF3COOH buffered with diethylamine, pH 2.5 (TFA-DEA, 
[ 11 ]), and eluted with TFA-DEA/CH3CN (20: 80). The purified 
extract was either lyophilized or run on HPLC after evapora- 
tion of CH3CN under vacuum. 
Ion-exchange separations were performed on S-Sepharose ® 
fast-flow from Pharmacia (Sweden), a strong cation-exchange 
medium, or Q-Sepharose ® fast-flow, a strong anion-exchange 
medium. Both media were packed in laboratory-made 
polypropylene mini-columns (1 cm I.D., 3 cm gel bed) fitted 
with polypropylene frits and operated by syringe pressure at a 
flow rate of 5 ml/min. The columns were equilibrated with 
0.1% TFA/CH3CN (80:20), pH 2.0, and eluted with the same 
buffer containing NaCl (for cation-exchange chromatography) 
or equilibrated with 10 mM NH4HCO3/CH3CN (80:20), pH 
8.0, and eluted with 0.5 M NH4HCO3/CH3CN (80:20), pH 8.0 
(for anion-exchange chromatography). In both cases, the frac- 
tions were desalted on Sep-Pak before lyophilization. 
2.5. Enzymatic digestions 
Enzymatic digestion was performed on Tris extracts from 15 
rat cortices which were concentrated on Sep-Pak (see 2.4) and 
lyophilized. Papain (EC 3.4.22.2, Boehringer-Mannheim, 
FRG), preincubated for 30 min at 25°C, was used at 40/~g/ml 
(final concentration) in 0.1 M NH4HCO3, pH 8.0, containing 
0.1 mM CaCl2 for 120 min at 37°C. Pepsin (EC 3.4.23.1, 
Boehringer-Mannheim, FRG) was used at 20/~g/ml in 1 mM 
HCI for 120 rain at 25°C. Phospholipase A2 (EC 3.1.1.4, 
Sigma, USA) was used in 0.5 M Tris-HC1, pH 7.5, at 100 U/ml 
(final concentration) for 120 min at 37°C. Controls were in- 
cubated in parallel in the absence of enzyme. Reactions were 
ended by degrading the enzymes at 100°C for 5 min (boiling 
water bath). The activity of the controls and of the experimental 
tubes was tested in the binding assay. 
2.6. Miscellaneous 
200-300 g male Wistar rats (Iffa-Credo, France), fed on 
standard laboratory chow, were used throughout. Protein con- 
centrations were measured according to Bradford [12] with the 
Bio-Rad protein assay kit (Bio-Rad, USA). Dialysis was per- 
formed in 24 A porosity Visking cellulose tubing (Union Car- 
bide, USA) against distilled water for 18 h at 4°C under 
continuous stirring. CH3CN was from SDS (France), TFA from 
Pierce (USA), other chemicals were from Merck (FRG). 
3. RESULTS 
Fig.1 shows that  a concent ra ted  Tris extract  
f rom rat cor tex was able to inhib i t  in a dose-  
dependent  manner  the [3H]Gl ipiz ide b ind ing on 
membranes  f rom rat cerebral  cortex.  The  d i lut ion 
curves for  the s tandard  and the extract  were 
paral le l ,  ind icat ing a s imi lar  behav iour  at the 
receptor  level o f  the drug and o f  the act ive compo-  
nent  present  in the extract .  It  may  be calculated 
f rom these data  that  1 g o f  rat cor tex conta ins  
1.5 pmol  Gl ip iz ide equiva lent  o f  act ive compo-  
nent.  Accord ing  to the respect ive af f in i ty  o f  
G l ip iz ide and G l ibenc lamide  for  the central  
su l fony lurea  receptor  [5], this cor responds  to 
-0 .1  pmol  G l ibenc lamide  qu iva lent /g  t issue (wet 
wt). It  must  be not iced that ,  i f  we d isregard the di f -  
ference in su l fony lurea  equiva lent ,  the exper iments  
on  b io log ica l  samples gave ident ical  results,  which-  
ever  Gl ip iz ide or  G l ibenc lamide  was used as  the 
t racer  or  the s tandard  (not shown).  The  act iv i ty 
present  in the Tris extract  was not  lost a f ter  dialysis 
(table 1), ind icat ing that  the act ive component  has 
a mo lecu la r  mass high enough to be reta ined by the 
24 A poros i ty  membrane .  This  rules out  the 
possib i l i ty  that  smal l  molecules  such as ions may 
have inter fered with the su l fony lurea  b inding.  
Runn ing  the concent ra ted  Tris extract  on  an ion-  
and  cat ion-exchange med ia  (table 1) ind icated that  
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Fig.l. Effects of unlabeUed Glipizide (standard) and of 
dilutions of a Sep-Pak concentrated Trig extract from rat 
cerebral cortex (extract) on the binding of [3H]Glipizide to 
membranes prepared from rat cerebral cortex. The highest 
dilution point (27) was placed on the standard curve and the 
other points placed according to their respective dilution. 
Similar results were observed in 5 repeated experiments. 
Table 1 
Effect of a concentrated Tris extract of rat cerebral cortex on 
the binding of [3H]Glipizide to membranes prepared from rat 
cerebral cortex after the following experiments 
Experiment Activity (070) 
(1) Dialysis control 100 
dialysed 92 
(2) Cation exchange (pH 2) void 6 
eluate 94 
(3) Anion exchange (pH 8) void 72 
eluate 28 
(1) Before (control) or after (dialyzed) dialysis in 24 A porosity 
Visking membrane. (2) Run on S-Sepharose fast-flow in 0.1 070 
TFA/CH3CN, 80:20 (cation exchange, pH 2). Void, void 
volume (not retained by the column); eluate, fraction eluted in 
0.1070 TFA/CH3CN, 80:20 containing 1M NaCI. (3) Run on 
Q-Sepharose fast-flow in 10 mM NI-hHCO3/CH3CN, 80:20 
(anion exchange, pH 8). Void, void volume (not retained by the 
column); eluate, 0.5 M NI-hHCO3/CH3CN, 80:20. Data are 
expressed as activity measured by the binding assay as 070 of the 
control (dialysis) or as 070 of the total activity recovered (cation- 
and anion-exchange chromatography). Similar results were 
obtained in three repeated experiments (dialysis) or two 
experiments (chromatographies) 
the active molecule is not retained by an anion ex- 
changer at pH 8, but is retained at pH 2 on a cat ion 
exchanger.  It may be eluted f rom this cat ion ex- 
changer at a salt concentrat ion o f  0.25 M (not 
shown).  Fig.2 provides direct evidence of  the pep- 
t idic nature of  the active molecule. Indeed, in- 
cubat ing the concentrated Tris extract with 
proteases uch as pepsin or papain resulted, under 
the condit ions used, in the loss o f  60 to 82°70 o f  the 
act ivity (fig.2). In contrast,  no degradat ion of  the 
act ivity was observed after incubat ion with 
phosphol ipase A2 (fig.2). Together,  these data sug- 
gest that the active molecule is a pept ide displaying 
a neutral  to slightly basic isoelectric point.  
The apparent  peptidic nature of  the active 
molecule led us to run the concentrated Tris extract 
on an HPLC system [11] set up for pur i fy ing pep- 
tides. A single peak of  activity was found (not 
shown),  indicat ing that reverse-phase HPLC may 
be used for isolating the active peptide. On the 
other hand,  the concentrated Tris extract was not 
suitable for this purpose,  and the possibi l i ty o f  ex- 
tract ing the active pept ide with more classical 
methods [10] was tested. It was found that very 
similar results were obta ined with either method 
(not shown). Fig.3 shows three pur i f icat ion steps 
o f  a batch of  100 g o f  rat cerebral  cortex extracted 
according to [10] with slight modif icat ions.  In the 
first step (C-8 column run at pH 7, f ig.3A), a single 
peak of  activity was observed at an acetonitr i le 
concentrat ion o f  28.5%. The corresponding frac- 
t ions were pooled and run on the next column. In 
100 
80 
i 60 40 
20 
0 
Caltrol  lqpsiu Pepsin P.Hpase A2 
Fig.2. Effects of a concentrated Tris extract on the binding of 
[3HlGlipizide to membranes prepared from rat cerebral cortex 
either before (control) or after enzymatic digestions by papain, 
pepsin or phospholipase A2. Data are expressed as °70 of control 
(incubated without enzyme). Data are the means ± SE of 3 
repeated experiments. 
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Fig.3. (A) High-performance liquid chromatography (HPLC) 
of an extract obtained from 100 rat cortices by the heat 
coagulation-acid extraction method [10] on a 1.0 I.D. x 30 cm 
column filled with Lichrosorb RP-8 and equilibrated with 
0.4 M CH3COONH4, pH 7.0, containing 3% propanol. The 
chromatography was developed by a linear gradient of 20-60% 
CH3CN in 50 min at 2 ml/min. The fractions corresponding to
the peak of activity indicated by the star was loaded on the next 
column (B). (B) HPLC of the fractions (*) from C-8 (A) on a 
1.0 × 30 cm pC-18 column equilibrated with 1% TFA-DEA 
[l l ] /CH3CN (80:20) and eluted with a linear gradient of 
20-50°70 CH3CN in 45 min at 6 ml/min. The peak of activity 
indicated by the star was loaded on the next column (C). (C) 
HPLC on a 0.39 x 30 cm Nucleosil CN column equilibrated 
with 0.loT0 TFA/CH~CN (90:10) of the fraction (*) in B. 
Elution was performed with a linear gradient of 10-50°10 in 
60 min at 1.5 ml/min. 0.5- (A) or l-rain fractions (B or C) were 
collected, lyophilized after evaporation of the organic solvent 
and tested in the binding assay. 
the second chromatography (C-18 column run at 
pH 2.5, fig.3B), a main peak of activity was visi- 
ble, eluting at 32°7o. This peak, run on a CN col- 
umn at pH 2, was resolved into two peaks of 
activity (fig.3C). This indicates either that a partial 
molecular modification occurred between step 2 
and step 3, or, more probably, that two molecular 
forms existed in the original extract, forms which 
were separated from each other by the charged 
cyano functional group of the CN column but not 
by the aliphatic functional groups of the C-8 or 
C-18 columns. It must be noticed that the column 
yields were 79°70 and 88070 for the C-18 and the CN 
steps and that the UV absorbance at all 
wavelengths of the active fractions declines trong- 
ly at each step to reach a very low level at the last 
one. This indicates that the purification factor was 
high from the original extract o the CN step. 
4. DISCUSSION 
The hypoglycemic sulfonylureas, a family of 
drugs of particular interest in the management of
diabetes meUitus [1], display specific membrane- 
bound receptors both at the level of the pancreatic 
B-cells [2,3] and in the central nervous system 
[4,5], a receptor which is linked to an ionic channel 
effector [6-9]. This led us to suggest hat this 
biologically relevant receptor is probably the 
natural recognition system of an endogenous 
ligand [5]. In the present study, we have focused 
our attention on the rat central sulfonylurea recep- 
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tor and thus on the possible presence of an en- 
dogenous ligand nearby the receptor, i.e. in the rat 
central nervous system. We show that an en- 
dogenous ligand is indeed present on the same side 
of the blood-brain barrier as the receptor itself and 
that this ligand is peptidic in nature, displaying 
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physico-chemical characteristics found in many 
regulatory peptides. The arguments for these 
assessments are as follows: (i) the ligand is found 
in the supernatant of the membrane preparation 
from the rat cerebral cortex, suggesting that it has 
been liberated by the disruption of the neuronal 
structure through the mild homogenization i a 
hypotonic medium, known to break the cell mem- 
brane, in particular the neuroregulatory molecule- 
containing nerve endings; (ii) the ligand is not 
dialysable, indicating a molecular size compatible 
with its suspected peptidic nature; (iii) a method 
widely used to  obtain an extract enriched in 
regulatory peptides [10] yielded a solution contain- 
ing the ligand at a concentration (per gram of 
tissue) similar to that obtained with the first type 
of extraction; (iv) the ligand binds to reverse-phase 
cartridges and may be eluted from them under con- 
ditions that are classically used for peptides [11]; 
(v) the ligand may be purified by reverse-phase 
HPLC under conditions as in (iv); (vi) the isoelec- 
tric point is neutral to slightly basic as assessed by 
the ion-exchange xperiments; (vii) the peptidic 
nature of the ligand is definitely substantiated by 
the disappearance of the activity after incubation 
with proteases. 
This peptidic nature of the endogenous ligand 
for the sulfonylurea receptor is reminiscent to that 
of ligands for other drug receptors uch as endor- 
phines for the morphine receptor [13] or diazepam 
binding inhibitor/endozepine for the benzodi- 
azepine receptor [14,15] as well as ligands for sites 
of other psychotropic drugs [16]. 
The presence in the rat central nervous ystem of 
a biologically relevant receptor and the existence 
nearby of an endogenous ligand for this receptor 
open up a new era of research on the complex 
regulatory processes occurring at the central evel. 
The isolation and chemical characterization f the 
peptide which binds to the sulfonylurea receptor 
will also shed a new light on the mode of action of 
this class of drugs used every day by millions of 
people. 
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